ispectamab debotansine (BMS-986352)
/ Sutro Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 11
Of
11
Go to page
1
August 30, 2024
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=47 | Terminated | Sponsor: Celgene | N=160 ➔ 47 | Active, not recruiting ➔ Terminated; Slow accrual
Enrollment change • Trial termination • Hematological Malignancies • Multiple Myeloma • Oncology
February 16, 2024
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=160 | Active, not recruiting | Sponsor: Celgene | Trial completion date: May 2025 ➔ Aug 2024 | Trial primary completion date: May 2025 ➔ Aug 2024
Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
January 11, 2024
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=160 | Active, not recruiting | Sponsor: Celgene | Trial completion date: Apr 2024 ➔ May 2025 | Trial primary completion date: Apr 2024 ➔ May 2025
Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
July 20, 2023
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=160 | Active, not recruiting | Sponsor: Celgene | Recruiting ➔ Active, not recruiting | Trial completion date: May 2025 ➔ Apr 2024 | Trial primary completion date: Dec 2024 ➔ Apr 2024
Enrollment closed • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
September 06, 2022
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=160 | Recruiting | Sponsor: Celgene | Trial primary completion date: May 2023 ➔ Dec 2024
Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
August 18, 2021
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1; N=160; Recruiting; Sponsor: Celgene; N=120 ➔ 160
Clinical • Enrollment change • Hematological Malignancies • Multiple Myeloma • Oncology
February 17, 2021
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1; N=120; Recruiting; Sponsor: Celgene; Trial completion date: Nov 2024 ➔ May 2025; Trial primary completion date: Nov 2024 ➔ May 2023
Clinical • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
September 21, 2020
Sutro Biopharma Named Best New Drug Developer at the 7th Annual World ADC
(PRNewswire)
- "Sutro Biopharma...announced that it has been recognized as Best New Drug Developer at the World ADC Digital Awards, held during the World ADC Digital Event...'The award recognizes our three innovative clinical development candidate ADCs. STRO-001 and STRO-002 are currently in Phase 1 clinical studies and CC-99712 is under investigation in a Phase 1b/2 clinical trial by our partner Bristol Myers Squibb'."
Commercial • Oncology
August 09, 2020
"#1 $BMY CC-99712 observations https://t.co/xESL6q0pqx"
(@Biotech2050)
November 07, 2019
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1; N=120; Recruiting; Sponsor: Celgene; Not yet recruiting ➔ Recruiting; Trial completion date: Nov 2022 ➔ Nov 2024; Trial primary completion date: Nov 2022 ➔ Nov 2024
Clinical • Enrollment open • Trial completion date • Trial primary completion date
August 05, 2019
Newly added product
(clinicaltrials.gov)
- P1, Multiple Myeloma
Pipeline update
1 to 11
Of
11
Go to page
1